1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Agenus Inc.

Agenus Inc.

AGEN
Agenus Inc.US flagNASDAQ Capital Market
3.30
USD
-0.09
- -
137.42MMarket Cap
Agenus Inc.
AGEN
(NASDAQ Capital Market)

Recent

price

3.30

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
4.17
2.77
13.51
2.05
2.34
6.35
5.19
8.71
6.64
22.23
10.22
25.83
6.96
8.74
4.82
3.84
3.79
Revenue per Share
-28.18
-24.19
-10.26
-22.33
-14.29
-22.52
-29.22
-24.57
-28.87
-15.98
-21
-2.11
-15.64
-13.75
-10.59
- -
1.97
Basic EPS, GAAP
-18.49
-16.39
0.77
-13.67
-13.74
-12.98
-21.24
-19.78
-24.32
-3.46
-16.53
-2.07
-16.22
-13.09
-7.4
-2.6
-2.68
Free Cash Flow per Basic Share
0.98
0.79
0.5
- -
0.15
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-724.22
-610.57
-523.74
-435.89
-231.17
-199.03
-207.75
-208.39
-212.35
-190.19
-169.73
-129.94
-121.16
-109.28
-101.65
-73.4
-65.64
Book Value per Share
-21.49
-23.52
-17.07
-4.74
-0.54
7.46
-17.89
-26.55
-45.08
-43.26
-28.73
1.27
-6.15
-9.92
-15.55
-10.26
-7.81
Tangible Book Value per Share
1
1
1
1
3
4
4
5
6
7
9
11
14
18
21
30
33
Basic Weighted Avg Shares
3
3
16
3
7
25
23
43
37
150
88
296
98
156
103
114
124
Sales/Revenue/Turnover
-647.47
-692.61
-42.23
-820.31
-524.86
-298.17
-467.47
-249.53
-340.25
-42.87
-131.58
12.59
-183.88
-102.43
-120.26
-18
6.3
Operating Margin (%)
3
2
2
1
2
14
5
6
6
7
7
7
7
14
13
10
7
Depreciation Expense
-22
-23
-11
-30
-42
-88
-127
-121
-160
-108
-181
-24
-220
-246
-227
- -
65
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-652.05
-844.63
-70.95
-987.54
-608.91
-354.12
-562.59
-281.48
-434.13
-71.75
-205.19
-8.09
-224.51
-157.22
-219.61
0.1
52.16
Profit Margin (%)
15
7
18
18
33
155
50
17
7
-36
-16
175
24
-143
-176
-190
-154
Working Capital
34
33
- -
5
5
114
131
142
13
21
53
55
76
75
85
10
10
LT Debt
-15
-21
-18
-4
23
71
-39
-76
-175
-231
-211
48
-55
-148
-306
-278
-228
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-5.86
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
12
46
31
LT Borrowings
24
- -
- -
LT Finance Leases
10
10
10
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
33
35
39
Market Capitalization
108
88
109

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
134
133
95
Cash, Cash Equivalents & STI
3
3
35
Accounts Receivable, Net
1
2
7
Inventories
- -
- -
- -
Total Current Liabilities
287
323
249
Payables & Accruals
110
108
102
ST Debt
12
46
31
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
2.28%
-13.96%
-9.32%
Free Cash Flow
125.46%
140.13%
-51.41%
Net Income, GAAP
74.44%
127.42%
-100.05%
Sales/Revenue/Turnover
53.79%
40.9%
10.37%
Total Cash Common Dividend
0.62%
0.66%
0.47%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
28
24
25
27
103
2025
24
26
30
34
114
2026
34
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-3.04
-2.52
-3.08
- -
-10.59
2025
-1.03
-1
2
- -
- -
2026
1.03
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Poxel S.A. (POXEL.PA)
Trevi Therapeutics, Inc. (TRVI)
BioCardia, Inc. (BCDAW)
Hemostemix Inc. (HEM.V)
Mirati Therapeutics, Inc. (MRTX)
Inner Mongolia Furui Medical Science Co., Ltd. (300049.SZ)
Business
Agenus Inc. (Nasdaq: AGEN), a clinical-stage immuno-oncology company founded in 1994 and headquartered in Lexington, Massachusetts, discovers, manufactures, and develops therapies that activate the immune system against cancer and infectious diseases. The company focuses on immune checkpoint modulating antibodies including botensilimab, a next-generation CTLA-4 antibody with enhanced Fc functionality, balstilimab, a PD-1 inhibitor, zalifrelimab, a CTLA-4 antibody, and earlier-stage candidates such as AGEN1571 (anti-ILT2), AGEN1777 (TIGIT bispecific), AGEN2373 (CD137), and AGEN1423 (CD73-TGFβ); adoptive cell therapies through its subsidiary MiNK Therapeutics, Inc. (Nasdaq: INKT); and vaccine adjuvants via SaponiQx, Inc., featuring proprietary QS-21 from cultured plant cells and platforms like Retrocyte Display for antibody discovery and AdenoJuice for personalized vaccines. Agenus operates primarily in the United States and Europe, with a pipeline targeting solid tumors such as metastatic colorectal cancer, cervical cancer, and other treatment-resistant malignancies, supported by in-house cGMP manufacturing capabilities. In recent developments, Agenus entered a $141 million strategic collaboration with Zydus Lifesciences in June 2025, exchanging its biologics CMC facilities in Emeryville and Berkeley, California, for $75 million upfront plus up to $50 million in contingent payments, alongside a $16 million equity investment from Zydus and an exclusive manufacturing agreement for botensilimab/balstilimab (BOT/BAL) to support clinical and commercial scale-up. Earlier, in May 2024, the company secured a $100 million royalty financing agreement with Ligand Pharmaceuticals, with potential syndication up to $200 million, to fund BOT/BAL's Phase 3 trial in relapsed/refractory microsatellite stable colorectal cancer and launch activities. Additional advancements include completing enrollment in a Phase 2 BOT/BAL trial in advanced MSS colorectal cancer, receiving Fast Track Designation, launching a Q4 2025 international trial across Canada, France, Australia, and New Zealand, and appointing Dr. José Iglesias as Chief Medical Affairs Officer to expand global access programs.

Company News

MCPAPIChat

  • zacks.com

    Why Is Agenus (AGEN) Down 9.6% Since Last Earnings Report?

  • zacks.com

    AGEN Early Access Revenues Signal a New Path Ahead of Approval

  • zacks.com

    Is Agenus Stock a Hold Amid Valuation and Funding Risks?

  • zacks.com

    AGEN BOT+BAL: What the BATTMAN Trial Means for mCRC

  • businesswire.com

    Agenus Announces Virtual 2026 Annual Shareholders Meeting

  • zacks.com

    AGEN vs. IOVA: Which Cancer Biotech Stock Has More Upside Potential?

  • zacks.com

    How Agenus' Pipeline Progress Unlock Its Next Growth Phase

  • seekingalpha.com

    Agenus: Weighing The Clinical Progress Against The Company's Cash

  • businesswire.com

    Agenus and Noetik Present ASCO 2026 Data Linking AI Analysis of Routine Pretreatment Tumor Pathology Images to Response and Survival with BOT+BAL in MSS Metastatic CRC

  • businesswire.com

    Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026

  • zacks.com

    AGEN Stock Dips 19.4% in a Month: Time to Buy, Hold or Sell?

  • businesswire.com

    Agenus Announces Publication of Phase 1b Botensilimab and Balstilimab Data in Post-Immunotherapy Hepatocellular Carcinoma in Liver Cancer

  • zacks.com

    Agenus (AGEN) Q1 Earnings and Revenues Miss Estimates

  • businesswire.com

    Agenus Reports First Quarter 2026 Financial Results and Highlights BOT+BAL Execution Across Global Access and Phase 3 Development

  • zacks.com

    Is Agenus (AGEN) Stock Outpacing Its Medical Peers This Year?

  • businesswire.com

    Agenus to Provide First Quarter 2026 Financial Report and Corporate Update

  • zacks.com

    Agenus (AGEN) Earnings Expected to Grow: What to Know Ahead of Q1 Release

  • zacks.com

    Bio-Techne's Q3 Earnings on Deck: What's in Store for the Stock?

  • zacks.com

    Vertex Gears Up to Report Q1 Earnings: What Investors Can Expect

  • zacks.com

    Here's How Henry Schein Is Placed Ahead of Q1 Earnings